Exco InTouch Achieves Quality Milestone with ISO9001:2008 Certification
Exco InTouch, has been approved to ISO9001:2008 by Lloyd’s Register Quality Assurance (LRQA), the world’s leading provider of independent assessment services.
This milestone certification has been awarded to Exco InTouch in recognition that the company has developed and implemented a quality management system built around processes of the highest standards and which meets or exceeds its customers’ requirements, whilst maximizing continual improvement.
The ISO9001:2008 certification underwrites the superior quality of Exco InTouch’s service delivery processes, making the company the only electronic clinical outcomes assessment (eCOA) provider to comply with ISO9001:2008, as well as the data privacy and security standards: Safe Harbor, EU Data Protection and HIPAA, which are essential when using a BYOD (Bring Your Own Device) approach in clinical and healthcare settings.
Tim Davis, CEO and founder of Exco InTouch commented: “We are delighted to have received this important certification. The capability underlines our commitment to quality and our ability to provide best in class services for our customers whilst marking us out as a gold standard provider in our field.”
Mark Wright, Head of Quality Assurance at Exco InTouch commented: “Quality of service is a key driver for us at Exco InTouch and we are very pleased to have been approved to ISO9001:2008 in recognition of the very high standard of products and services that we provide in mobile and digital technology data capture and patient engagement solutions. We are achieving ever increasing customer service levels to meet the needs of our clients head on and we are proud to have been formally recognized in this regard.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.